Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. (Q38189898)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 February 2014

Language	Label	Description	Also known as
English	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.	scientific article published on 17 February 2014

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

phase III clinical trial

0 references

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Georg A. Bjarnason

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Cezary Szczylik

5

object named as

Cezary Szczylik

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

11

object named as

Ugo De Giorgi

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Nicholas J Vogelzang

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Cora N Sternberg

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Jakub Zolnierek

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Christian Kollmannsberger

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Bohuslav Melichar

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Viktor Grünwald

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Ian D Davis

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Jae-Lyun Lee

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Gladys Urbanowitz

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Can Cai

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Matthew Squires

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Mahtab Marker

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Michael M Shi

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Bernard Escudier

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

17 February 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

286-296

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

23 June 2018

Temsirolimus: a safety and efficacy review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

23 June 2018

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

23 June 2018

Treatment selection in metastatic renal cell carcinoma: expert consensus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

23 June 2018

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

23 June 2018

Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

23 June 2018

The role of fibroblast growth factors in tumor growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

23 June 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

23 June 2018

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

23 June 2018

Drug-induced liver injury: Hy's rule revisited

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

23 June 2018

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

23 June 2018

Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

23 June 2018

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

23 June 2018

Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

23 June 2018

Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

31 August 2018

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

31 August 2018

Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

31 August 2018

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

31 August 2018

In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719485

31 August 2018

Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970030-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970030-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970030-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970030-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970030-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Fulminant acneiform eruptions after administration of dovitinib in a patient with renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970030-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70030-0

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24556040%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38189898&oldid=1563861312"